Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Matteo Santoni, Francesco Massari, Zin W Myint...
https://pubmed.ncbi.nlm.nih.gov/37369815/Actively Recruiting
Led by Hospital of Macerata · Updated on 2025-11-26
1220
Participants Needed
1
Research Sites
173 weeks
Total Duration
Researchers are conducting the ARON-1 Study, an international and multicenter observational study, to gather worldwide experiences on using immuno-combination therapies for patients with metastatic renal cell carcinoma RCC. This research includes two supplementary studies focused on analyzing genomic signatures from tumor samples and characterizing immune cell populations in patients treated with first-line immuno-combinations for advanced RCC. The treatments being evaluated include combinations such as pembrolizumab plus axitinib, nivolumab plus ipilimumab, nivolumab plus cabozantinib, pembrolizumab plus lenvatinib, avelumab plus axitinib, and atezolizumab plus bevacizumab. These therapies are studied as first-line treatments for metastatic RCC, allowing researchers to compare outcomes across different immuno-combination regimens. Participants provide data retrospectively, with researchers reviewing clinical outcomes such as progression-free survival, overall survival, and overall response rate. Additional analyses focus on treatment efficacy in elderly patients, patients with bone or brain metastases, and those with non-clear cell RCC. The study also examines the prognostic impact of smoking and obesity. Data collection continues until September 2027, with no direct intervention or active treatment administration during the study period.
CONDITIONS
International Multicentric Study ARON-1
M
Matteo Santoni, MD, PhD
G
Giulia Sorgentoni, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hospital of Macerata
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Until disease progression or discontinuation
Participants receive immuno-combination drug therapies as first-line treatment for metastatic renal cell carcinoma.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Matteo Santoni, Francesco Massari, Zin W Myint...
https://pubmed.ncbi.nlm.nih.gov/37369815/Chiara Ciccarese, Thomas Büttner, Linda Cerbone...
https://pubmed.ncbi.nlm.nih.gov/39243397/Matteo Santoni, Francesco Massari, Zin W Myint...
https://pubmed.ncbi.nlm.nih.gov/37062658/Hospital of Macerata
Lead Sponsor